OH2 oncolytic virus
Phase 1Biologic
OH2 oncolytic virus is one of 11 biologic programs targeting Digestive System Neoplasm. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Digestive System Neoplasm
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Beyfortus
BeiGenePhase 2
Herceptin
OOrganon and Co
Phase 2
Pyrotinib
HHengrui Therapeutics, Inc.
Phase 2
Adrucil
EElorac, Inc.
Phase 1
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 1
LP002
TTaizhou HoudeAoke Biomedical Co., Ltd.
Phase 1
IM96 CAR-T Cells
BBeijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1
Ineo-Vac-R01
SSir Run Run Shaw Hospital
Phase 1
OH2 oncolytic virus
TTaizhou HoudeAoke Biomedical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OH2 oncolytic virus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details